Firas El Chaer, MD
Firas El Chaer, MD, an assistant professor of medicine who specializes in hematology and oncology, will present preliminary clinical data evaluating investigational agent TP-3654 at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held December 10-13 in New Orleans, Louisiana.
The presentation will include preliminary clinical data from patients enrolled in a Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM-1 kinase inhibitor, in patients with myelofibrosis previously treated with or ineligible for JAK inhibitor therapy.
Data in the dose escalation portion of the study show encouraging signs of clinical activity in spleen volume reduction, symptom improvement and cytokine reduction with TP-3654 monotherapy in patients previously treated with JAK inhibitors. In this study, TP-3654 was well-tolerated with limited myelosuppressive adverse events.
University of Virginia is one of the international sites for this clinical trial using TP-3654 in patients with myelofibrosis and the principal investigator is Dr. Firas El Chaer. The clinical trial is currently enrolling patients at Study of Oral TP-3654 in Patients with Myelofibrosis.